Cash runway is tight at ~S$1.46M with a ~S$1.65M semi-annual burn rate, suggesting the need for additional capital within 6-12 months. The recent S$1M director loan and ATM capacity (US$4.3M, mostly undrawn) are potential sources, but the lack of therapeutic revenue and early-stage pipeline mean any financing event would likely be dilutive. Monitor for a capital raise announcement or clinical trial updates (ANGELICA Phase I, CTM-GDT IND).
Price Chart
Executive Summary
CytoMed Therapeutics reported H1 2026 results showing a net loss of S$1.79 million (US$1.39 million), a 20.1% improvement from the S$2.25 million loss in H1 2025, driven by lower research and other expenses. Revenue from private blood banking services was essentially flat at S$157,289 (+0.9% YoY). Cash burn continues, with cash and bank balances declining to S$1.46 million from S$2.10 million at year-end 2025, and the company relied on a S$699,600 director loan and subsidiary share issuance to fund operations. A subsequent S$1 million shareholder loan from a director was signed on September 29, 2026.
Key Facts
- Net loss for H1 2026 was S$1.79 million (US$1.39 million), improved 20.1% from S$2.25 million in H1 2025.
- Revenue was essentially flat at S$157,289 (+0.9% YoY), entirely from private blood banking services.
- Cash and bank balances fell to S$1.46 million as of June 30, 2026, from S$2.10 million at December 31, 2025.
- Net cash used in operating activities was S$1.65 million, roughly flat vs S$1.60 million in H1 2025.
- Proceeds of S$699,600 from a director loan and S$300,000 from subsidiary share issuance to non-controlling interests supported financing.
- On September 29, 2026, the company entered a S$1 million shareholder loan agreement with a director at 2.75% interest for six months.
- No therapeutic product revenue; all product candidates remain in clinical/pre-clinical stages.
- ATM offering program has capacity of up to US$4.30 million; only US$237,550 raised to date.
- Accumulated losses reached S$20.6 million as of June 30, 2026.
- A SC 13D/A was filed on July 24, 2026 by Chairman Choo Chee Kong, indicating activist stake context.
Financial Impact
Net loss improved ~20% YoY to S$1.79M, but cash burn continues at ~S$1.65M per half-year; cash runway appears less than 12 months without additional financing.
Risk Factors
- Cash burn rate may exhaust current cash within ~12 months absent additional financing.
- No approved therapeutic products or near-term revenue from cell therapy pipeline.
- Reliance on director loans and ATM offerings for liquidity; further dilution likely.
- Clinical-stage pipeline with no guarantee of regulatory approval or commercial success.
- Activist stake (SC 13D/A) by Chairman Choo Chee Kong adds governance uncertainty.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-045045 |
| Exhibit: ex99-2.htm | 0001493152-26-045045 |
| Document: form6-k.htm | 0001493152-26-045045 |
| Document: 0001493152-26-045045-index-headers.html | 0001493152-26-045045 |
| Document: 0001493152-26-045045-index.html | 0001493152-26-045045 |
| Document: 0001493152-26-045045.txt | 0001493152-26-045045 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC 13G/A | $0.9190 $0.9262 | ▲ +0.78% | ▲ +0.07% | $0.9262 (+0.78%) |
Oct 16, 2026 10d ago | SC 13D/A | $0.8799 $0.8520 | ▼ −3.17% | ▼ −3.59% | $0.9262 (+5.26%) |
Oct 13, 2026 13d ago | SC 13D/A | $0.8700 $0.8599 | ▼ −1.16% | ▼ −0.08% | $0.9262 (+6.46%) |
Oct 9, 2026 16d ago | 6-K | $0.8114 $0.8700 | ▼ −7.22% | ▼ −7.23% | $0.9262 (−14.15%) |
Sep 30, 2026 26d ago | 6-K | $0.8430 $0.8999 | ▼ −6.75% | ▼ −6.57% | $0.9262 (−9.87%) |
May 15, 2026 23w ago | 6-K | $1.16 $1.21 | ▲ +4.31% | ▲ +4.37% | $0.9262 (−20.16%) |
May 11, 2026 24w ago | 6-K | $0.8090 $0.7690 | ▼ −4.94% | ▼ −4.81% | $0.9262 (+14.49%) |
Mar 31, 2026 29w ago | 6-K | $1.00 $1.03 | ▲ +3.00% | ▲ +2.25% | $0.9262 (−7.38%) |
Mar 31, 2026 29w ago | 20-F | $1.00 $1.03 | ▲ +3.00% | ▲ +2.25% | $0.9262 (−7.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers